CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, pros...
Alexandria, Virginia, United States and 12 other locations
predicted neoantigen load. Prevalence estimates of MMR deficiency across solid tumor types range from 1% to 20% depending on the type of ma ...
Phase 2
Baltimore, Maryland, United States
Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for me ...
Phase 1
Towson, Maryland, United States and 13 other locations
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer...
Phase 2
Baltimore, Maryland, United States
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate...
Phase 3
Washington, District of Columbia, United States and 30 other locations
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate...
Phase 2
Bethesda, Maryland, United States and 22 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Washington, District of Columbia, United States and 107 other locations
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate...
Phase 4
Baltimore, Maryland, United States and 9 other locations
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate...
Alexandria, Virginia, United States and 5 other locations
Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate...
Phase 3
Washington, District of Columbia, United States and 34 other locations
Clinical trials
Research sites
Resources
Legal